Our study demonstrated that ABT-263 promoted GSK-3β inactivation and Mcl-1 stability via Akt pathway, indicating that inhibition of Akt may be a good strategy to sensitize ABT-263 in HCC treatment. This evidence concerns the gene AKT1 and hepatocellular carcinoma.